12

CLAIMS

1

2

3

5

6

7

8

9

1

2

1. A method of preventing thrombosis formation on a liquid-containing surface of a liquid delivery system, the liquid delivery system being connected to a patient for delivery of a liquid to said patient, the method comprising a regimen selected from the group consisting of:

- A) contacting said surface with a thrombosis-preventing liquid containing taurolidine, taurultam or a mixture thereof, said thrombosis-preventing liquid further containing an anticoagulant agent; and
- B) first contacting said surface with a solution containing a thrombosispreventing amount of an anticoagulant agent, and thereafter contacting said surface with a solution containing taurolidine, taurultam or a mixture thereof.
- 2. The method of claim 1 wherein the solution or liquid containing taurolidine, taurultam or mixture thereof is contacted with said surface for at least about 1 hour.
- 3. The method of claim 2 wherein said solution or liquid containing taurolidine, taurultam or mixture thereof is sealed in said delivery system for a period of at least 12 hours.
- 4. The method of claim 3 wherein said solution or liquid containing taurolidine, taurultam or mixture thereof which is sealed in said delivery system, is replaced at least about daily.
- 5. The method of claim 1 wherein, when first contacting said surface with the anticoagulant
 solution, said surface is flushed with said anticoagulant-containing solution.
- 1 6. The method of claim 5 wherein the solution containing taurolidine, taurultam or a mixture thereof is contacted with said surface for at least about 1 hour.
- 7. The method of claim 6 wherein said solution containing taurolidine, taurultam or a mixture thereof is sealed in said delivery system for a period of at least about 12 hours.
- 8. The method of claim 7 wherein the solution containing taurolidine, taurultam or a mixture thereof which is sealed in said delivery system is replaced at least about daily.

- 9. The method of claim 1 wherein the anticoagulant-containing solution is contacted with
- 2 said surface by injecting the anticoagulant-containing solution into said liquid delivery
- 3 system and then removing said anticoagulant-containing solution from said liquid delivery
- 4 system.
- 1 10. The method of claim 9 wherein the solution containing taurolidine, taurultam or a
- 2 mixture thereof is contacted with said surface for at least about 1 hour.
- 1 11. The method of claim 10 wherein the solution containing taurolidine, taurultam or a
- 2 mixture thereof is sealed in said delivery system for a period of at least about 12 hours.
- 1 12. The method of claim 11 wherein the solution containing taurolidine, taurultam or a
- 2 mixture thereof which is sealed in said delivery system, is replaced at least about daily.
- 1 13. The method of claim 1 wherein said solution or liquid containing taurolidine, taurultam
- or a mixture thereof contains from about 0.5 to about 3% by weight of taurolidine, or from
- about 1 to about 7.5% by weight of taurultam.
- 1 14. The method of claim 1 wherein said anticoagulant agent is selected from the group
- 2 consisting of sodium citrate, aprotinin, hirudin, desirudin, danaparoid, danaparoid-sodium,
- 3 heparin, pentosan, pentosanpolysulfate-sodium, ticlopidine, clopidogrel, and mixtures
- 4 thereof.
- 1 15. The method of claim 14 wherein said anticoagulant is present in an amount within a
- 2 range of from about 0.1-10mg.
- 1 16. A composition for use in the method of claim 1, comprising a pharmaceutically-
- 2 acceptable liquid containing taurolidine, taurultam or a mixture thereof and further including
- 3 an anticoagulant agent.

- 1 17. The composition of claim 16 wherein said anticoagulant agent is selected from the group
- 2 consisting of aprotinin, hirudin, desirudin, danaparoid, danaparoid-sodium, pentosan,
- 3 pentosanpolysulfate-sodium, ticlopidine, clopidogrel, and mixtures thereof.
- 1 18. The composition of claim 16 wherein said anticoagulant agent is heparin.
- 1 19. The composition of claim 16 wherein said anticoagulant is sodium citrate.
- 1 20. The composition of claim 16 wherein said taurolidine is present in an amount of from
- about 0.5 to about 3% by weight or said taurultam is present in an amount of from about 1 to
- about 7.5% by weight, and said anticoagulant agent is present in an amount within a range of
- 4 from about 0.01 to about 5% by weight.